Virology Research Centre, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, Brazil.
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Viruses. 2021 Oct 22;13(11):2127. doi: 10.3390/v13112127.
A SARS-CoV-2 B.1.1.7 variant of concern (VOC) has been associated with increased transmissibility, hospitalization, and mortality. This study aimed to explore the factors associated with B.1.1.7 VOC infection in the context of vaccination. On March 2021, we detected SARS-CoV-2 RNA in nasopharyngeal samples from 14 of 22 individuals vaccinated with a single-dose of ChAdOx1 (outbreak A, = 26), and 22 of 42 of individuals with two doses of the CoronaVac vaccine (outbreak B, = 52) for breakthrough infection rates for ChAdOx1 of 63.6% and 52.4% for CoronaVac. The outbreaks were caused by two independent clusters of the B.1.1.7 VOC. The serum of PCR-positive symptomatic SARS-CoV-2-infected individuals had ~1.8-3.4-fold more neutralizing capacity against B.1.1.7 compared to the serum of asymptomatic individuals. These data based on exploratory analysis suggest that the B.1.1.7 variant can infect individuals partially immunized with a single dose of an adenovirus-vectored vaccine or fully immunized with two doses of an inactivated vaccine, although the vaccines were able to reduce the risk of severe disease and death caused by this VOC, even in the elderly.
一种令人关注的 SARS-CoV-2 B.1.1.7 变异株（VOC）与传染性增加、住院和死亡率升高有关。本研究旨在探讨在接种疫苗的情况下与 B.1.1.7 VOC 感染相关的因素。2021 年 3 月，我们在 26 名接种一剂 ChAdOx1 疫苗的 22 名个体（爆发 A）和 52 名接种两剂 CoronaVac 疫苗的 42 名个体（爆发 B）的鼻咽样本中检测到 SARS-CoV-2 RNA，ChAdOx1 和 CoronaVac 的突破性感染率分别为 63.6%和 52.4%。这些爆发是由 B.1.1.7 VOC 的两个独立集群引起的。PCR 阳性症状性 SARS-CoV-2 感染个体的血清对 B.1.1.7 的中和能力比无症状个体的血清高 1.8-3.4 倍。这些基于探索性分析的数据表明，B.1.1.7 变体可以感染部分接种一剂腺病毒载体疫苗或完全接种两剂灭活疫苗的个体，但这些疫苗能够降低这种 VOC 引起的严重疾病和死亡的风险，即使是在老年人中。
